AKEBIA THERAPEUTICS, INC. (AKBA) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 219.06M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $219.06M | (m) | (m) |
| 2026-03-31 | (m) | $232.40M | (m) | (m) |
| 2025-12-31 | (m) | $236.20M | (m) | (m) |
| 2025-09-30 | (m) | $225.07M | (m) | (m) |
| 2025-06-30 | (m) | $203.73M | (m) | (m) |
| 2025-03-31 | (m) | $184.91M | (m) | (m) |
| 2024-12-31 | (m) | $160.18M | (m) | (m) |
| 2024-09-30 | (m) | $169.88M | (m) | (m) |
| 2024-06-30 | (m) | $174.50M | (m) | (m) |
| 2024-03-31 | (m) | $187.22M | (m) | (m) |
| 2023-12-31 | (m) | $194.62M | (m) | (m) |
| 2023-09-30 | (m) | $194.21M | (m) | (m) |
| 2023-06-30 | (m) | $200.88M | (m) | (m) |
| 2023-03-31 | (m) | $271.03M | (m) | (m) |
| 2022-12-31 | (m) | $292.60M | (m) | (m) |
| 2022-09-30 | (m) | $297.03M | (m) | (m) |
| 2022-06-30 | (m) | $296.82M | (m) | (m) |
| 2022-03-31 | (m) | $222.97M | (m) | (m) |
| 2021-12-31 | (m) | $213.58M | (m) | (m) |
| 2021-09-30 | (m) | $210.67M | (m) | (m) |
| 2021-06-30 | (m) | $221.90M | (m) | (m) |
| 2021-03-31 | (m) | $259.13M | (m) | (m) |
| 2020-12-31 | (m) | $295.31M | (m) | (m) |
| 2020-09-30 | (m) | $308.16M | (m) | (m) |
| 2020-06-30 | (m) | $340.15M | (m) | (m) |
| 2020-03-31 | (m) | $350.81M | $105.39M | (m) |
| 2019-12-31 | (m) | $335.00M | $108.94M | (m) |
| 2019-09-30 | (m) | $325.30M | (m) | (m) |
| 2019-06-30 | (m) | $286.49M | (m) | (m) |
| 2019-03-31 | (m) | $234.48M | (m) | (m) |
| 2018-12-31 | (m) | $207.74M | $6.25M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $181.23M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.53M | (m) | (m) |
| 2016-09-30 | (m) | $0.00 | (m) | (m) |
| 2016-06-30 | (m) | $0.00 | (m) | (m) |
| 2016-03-31 | (m) | $0.00 | (m) | (m) |
| 2015-12-31 | (m) | $0.00 | (m) | (m) |
| 2015-09-30 | (m) | $0.00 | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $0.00 | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |